Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20206152 | 0.95 | NAMPT (0.59) | GAAKDM4EMEN1KMT2AGRM5 | |
| SCHEMBL24021427 | 0.92 | GRM5 (0.49) | GAAKDM4EMEN1KMT2AGRM5 | |
| SCHEMBL20206127 | 0.91 | NAMPT (0.57) | GAAKDM4EMEN1KMT2AGRM5 | |
| SCHEMBL20206125 | 0.91 | NAMPT (0.52) | GAAKDM4EMEN1KMT2AGRM5 | |
| SCHEMBL23898933 | 0.90 | GAA (0.61) | GAAKDM4EMEN1KMT2ANAMPT | |
| SCHEMBL20189983 | 0.87 | STAT3 (0.52) | GAAKDM4EMEN1KMT2AGRM5 | |
| SCHEMBL20206126 | 0.87 | KAT6A (0.52) | MEN1KMT2AGRM5NAMPTNPC1 | |
| SCHEMBL20206136 | 0.83 | NAMPT (0.45) | GAAKDM4EMEN1KMT2AGRM5 | |
| SCHEMBL20206222 | 0.82 | ACKR3 (0.47) | GAAKDM4EMEN1KMT2AGRM5 | |
| SCHEMBL20206250 | 0.81 | GAA (0.42) | GAAKDM4EMEN1KMT2AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043405-A1 | POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1 | DANA-FARBER CANCER INSTITUTE, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4125895-A1 | POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1 | Dana-Farber Cancer Institute, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-3544970-B1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2018098367-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043405-A1 | POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1 | IRAK1, IRAK2, IRAK3 | GAA 2558/4885KDM4E 1105/4885MEN1 3487/4885 |
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | IRAK1, IRAK4, IRAK2 | GAA 2902/4885KDM4E 1670/4885MEN1 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.